Abstract: These and other objects of this invention are achieved by providing a novel method and compositions for the clinical treatment of chronic inflammatory diseases. This invention involves use of systemically administered compositions which include primary amine derivatives of benzoic acid as carbonyl trapping agents. These primary therapeutic agents act by chemically binding to and sequestering the aldehyde and/or ketone products of lipid peroxidation. Increased levels of lipid peroxidation have been repeatedly demonstrated as a part of the non-enzymatic “inflammatory cascade” process which underlies the secondary etiology of chronic inflammatory diseases. p-Aminobenzoic acid (or PABA) is an example of the primary therapeutic agent of the present invention. PABA has a small molecular weight, is water soluble, has a primary amine group that reacts with carbonyl-containing metabolites under physiological conditions and is tolerated by the body in relatively high dosages and for extended periods.

Abstract: A system for releasing a drug specifically in the colon of the gastrointestinal tract, which comprises a drug (b) coated with an organic acid-soluble polymer material (a), and a saccharide (c) which rapidly generates an organic acid by the action of enterobacteria in the lower part of the gastrointestinal tract; a colon-specific drug release oral preparation, which comprises a composition comprising a drug (b) coated with an organic acid-soluble polymer material (a) and a saccharide (c) which rapidly generates an organic acid by the action of enterobacteria in the lower part of the gastrointestinal tract, said composition being coated with an enteric coating polymer material (d). The invention provides a drug release system and a preparation which utilize enterobacteria, which do not form harmful substances due to the release-starting mechanism, show rapid degradation, and have higher colon specificity.

Abstract: Skin irritation, such as diaper rash, appearing when the skin is allowed to remain in contact with proteolytic enzymes found in feces is prevented by inactivating the fecal proteolytic enzymes by contact with organophilic clays. The organophilic clays are applied to the skin in areas likely to come into contact with feces or to garments such as diapers. A composition suitable for practicing the method of the invention comprises an amount of an organophilic clay effective to inactivate irritating fecal proteolytic enzymes dispersed in a pharmaceutically acceptable non-toxic dermatological vehicle. A fabric incorporating organophilic clay, preferably dispersed in a matrix of a superabsorbent polymer is useful for preparing diapers for infants that can help to prevent skin irritation by fecal enzymes.

Abstract: The invention relates to a compact member comprising a plurality of porous cellulose matrices (PCMs), and providing extended release of an active compound located in the pores of said PCMs together with a release modifying agent. The friability of the compact member is less than 2.1%, and the disintegration time in-vitro of said compact member is less than 240 minutes. The compact member is manufactured by exposing a plurality of PCMs to an active compound and a release modifying agent, in optional sequence or mixture, for a time sufficient for said active compound and release modifying agent to fill the pores in said PCMs to a preselected level. The PCMs are subsequently compacted to a desired shape. The invention further relates to use of the compact members for administration of a drug.

Abstract: The present invention is directed to monomeric and polymeric compositions based upon polymeric urethane surfactants which are derived from linear, branched, or aromatic compounds of synthetic or natural origin, preferably from tertiary amines and diisocyanate compounds. The urethane polymers of the present invention may be in the form of betaines, quaternium salts, tertiary amine salts or N-oxides. The compounds of the present invention may be incorporated into personal care formulations such as cosmetics, dental care products and toiletries to improve at least one and preferably two or more characteristics of such formulations.

Abstract: A method for creating a barrier to protect wood materials for house construction or wooden structures such as houses from humidity, moisture and/or biological attacks, such as wood decaying fungi and termites, is disclosed. The method is to treat wood itself or, preferably, the ground surface under the floor with a liquid containing a synthetic resin emulsion and an anti-fungal and wood preservative agent and/or a pesticide such as termite-controlling agent, and further, a foaming agent. The barrier contains a selected copolymer of vinyl acetate and a polyurethane polymer.

Abstract: A gastric remaining preparation having a configuration entirely different from that of the conventional ones. It comprises a swollen molding having a mesh-like cross-section and an apparent density of less than 1, containing an acid-resistant polymer compound as a predominant component as well as at least an auxiliary blowing agent and a drug substance. The molding can be produced by using a multi-screw extruder.

Abstract: A pearlescent composition containing: (a) a dialkyl ether corresponding to formula (I): R1—O—R2 wherein R1 and R2, independently of one another, represent linear or branched alkyl and/or alkenyl groups having from 12 to 22 carbon atoms; (b) a silicone compound; and (c) an emulsifier selected from the group consisting of alkyl oligoglycosides, alkenyl oligoglycosides, fatty acid-N-alkyl polyhydroxyalkylamides, alkyl ether sulfates, betaines, and mixtures thereof.

Abstract: Compositions for topical ophthalmic application comprising an aqueous mixture of a non-steroidal anti-inflammatory agent. The compositions are formulated with a pH and concentration of agent chosen to maintain at least some of the therapeutic agent of the formulation in suspension.

Abstract: A keratotic plug remover composition comprising a polymer compound having a salt forming group is disclosed. The composition according to the invention can effectively remove keratotic plugs in the skin pores, so that the conspicuousness of the skin pores is mitigated and clean and healthy skin pores can be maintained. The composition does not hurt the skin.

Abstract: Stable aqueous dispersions of 1,2-benzisothiazolin-3-one containing Xanthan gum which is substantially free from organic solvents.

Abstract: A method for the controlled release of a biologically active agent wherein the agent is released from a hydrophobic, pH-sensitive polymer matrix is disclosed and claimed. In one embodiment, the polymer matrix swells when the environment reaches pH 8.5, releasing the active agent. A polymer of hydrophobic and weakly acidic comonomers is disclosed for use in the controlled release system. In another embodiment, weakly basic comonomers are used and the active agent is released as the pH drops. Further disclosed is a specific embodiment in which the controlled release system may be used. The pH-sensitive polymer is coated onto a latex catheter used in ureteral catheterization. A common problem with catheterized patients is the infection of the urinary tract with urease-producing bacteria. In addition to the irritation caused by the presence of the bacteria, urease produced by these bacteria degrade urea in the urine, forming carbon dioxide and ammonia. The ammonia causes an increase in the pH of the urine.

Abstract: Methods and compositions are disclosed for providing prolonged release of therapeutic agents by way of in situ stereotaxic implantation in specific loci, including pathways, to treat known disorders. One or more microstructures comprising therapeutic agents and pharmaceutically acceptable carriers are implanted, for example, through a cannula. The microstructures are of a sufficient size and shape to prevent dispersion from the implant site.

Abstract: Disclosed is a method of inhibiting the formation of scale on reactor surfaces in contact with a polymerizing vinyl monomer comprising contacting said monomer with a terpolymer which comprises the condensation reaction product of (A) an aromatic compound that contains the group where Q is OR or SR and R is hydrogen, alkyl from C1 to C15, or aryl, alkaryl, or aralkyl from C6 to C15: (B) about 0.1 to about 10 moles of a carbonyl compound per mole of said aromatic compound; and (C) about 0.1 to about 10 moles of a thiourea per mole of said aromatic compound.

Abstract: Particles of coordinated complex comprising a basic, hydrous polymer and a capacitance adding compound, as well as methods for their production, are described. These complexes exhibit a high degree of bioactivity making them suitable for a broad range of applications through their incorporation into conventional vehicles benefiting from antimicrobial and similar properties.

Abstract: The present invention relates to insecticidal compositions based on polymers, processes for their preparation and their use for controlling insects which occur in interior rooms.

Abstract: A transparent gel air freshener and method of preparing the same. The gel composition comprises an aqueous gel, a fragrance, a surfactant and a co-solvent. The gel is transparent and free from visible particles and inhomogeneities, has a uniform texture and a continuous structure, and includes volatile scented components. The gel is capable of suspending solids such as botanicals therein for decorative effect. The method provides for preparation of a such a gel air freshener, including the suspension of botanicals therein, while maintaining the clarity, texture, and structure of the gel. The method includes the steps of preparing a gel composition and cooling the gel composition. Botanicals may be added to the gel composition when it has gelled enough to support die botanical on the gel surface.

Abstract: The present invention relates to a method for sequestering bile acids in a patient and to particular polymers for use in the method. The method comprises administering a therapeutically effective amount of a guanidinium moiety-containing polymer composition to a mammal, such as a human, whereby bile acids are sequestered. The polymers of the invention comprise guanidinium moieties and optionally, additional substituents such as a hydrophobic group, a quaternary ammonium-containing group or a combination thereof.

Abstract: A method of treatment for impotency is provided. The method involves the administration of nitric oxide by a nitric oxide-releasing agent capable of providing a penile erection-inducing amount of nitric oxide to the corpus cavernosum of the penis of an impotent male animal. Also provided is a nitric oxide delivery means for use in the method.

Abstract: The invention relates to new microparticles containing active ingredients, which contain at least one gas or a gaseous phase in addition to the active ingredient(s), agents containing these particles (microparticulate systems), their use for ultrasound-controlled in vivo release of active ingredients, as well as a process for the production of particles and agents.